After discussions with the FDA, Oncopeptides AB has initiated the preparation for submitting a New Drug Application for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.
A new model aims to change the standard of care around medical debt by addressing the financial toll of cancer using a multidisciplinary, tumor board model approach. Now, recent five-year data shows that it’s working.
